Role of cerebellar dopamine D3 receptors in modulating exploratory locomotion and cataleptogenicity in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 50, Issue , 2014, Pages 157-162

  Shimizu, Saki ^a   Tatara, Ayaka ^a   Sato, Maho ^a   Sugiuchi, Tomone ^a   Miyoshi, Satoshi ^a   Andatsu, Saki ^a   Kizu, Tomoya ^a   Ohno, Yukihiro ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Antipsychotics; Catalepsy; Cerebellum; Dopamine D3 receptors; Locomotor activity; Microinjection

Indexed keywords

2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; AD 6048; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; UNCLASSIFIED DRUG; (5,6-DIMETHOXYINDAN-2-YL)DIPROPYLAMINE; 7-HYDROXY-2-N,N-DIPROPYLAMINOTETRALIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TETRALIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; HALOPERIDOL-INDUCED CATALEPSY; LOCOMOTION; MALE; MOTOR PERFORMANCE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REGULATORY MECHANISM; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; EXPLORATORY BEHAVIOR; MICROINJECTION; PHYSIOLOGY;

ANIMALS; CATALEPSY; CEREBELLUM; CORPUS STRIATUM; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXPLORATORY BEHAVIOR; HALOPERIDOL; INDANS; MALE; MICROINJECTIONS; NUCLEUS ACCUMBENS; PIPERAZINES; PYRIDINES; RATS; RECEPTORS, DOPAMINE D3; TETRAHYDRONAPHTHALENES;

EID: 84892171963     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.12.013     Document Type: Article

References (45)

1. 3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci 1996, 93:1945-1949.
2. Asanuma K., Tang C., Ma Y., Dhawan V., Mattis P., Edwards C., et al. Network modulation in the treatment of Parkinson's disease. Brain 2006, 129:2667-2678.
3. 3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:718-726.
4. 2 receptor mRNA. Brain Res 1991, 564:203-219.
5. 3 receptor agonist, (+)-PD 128907, in the rat. Neuropharmacology 1996, 35:285-294.
6. Carpenter M.B. Connectivity patterns of thalamic nuclei implicated in dyskinesia. Stereotact Funct Neurosurg 1989, 52:79-119.
7. Collins G.T., Truccone A., Haji-Abdi F., Newman A.H., Grundt P., Rice K.C., et al. Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther 2009, 329:210-217.
8. Daly S.A., Waddington J.L. Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology 1993, 32:509-510.
9. 3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl) 1996, 124:231-240.
10. 3 receptor in the rat brain. Neuroscience 1995, 65:731-745.
11. Fujii T., Sakai M., Nagatsu I. Immunohistochemical demonstration of expression of tyrosine hydroxylase in cerebellar Purkinje cells of the human and mouse. Neurosci Lett 1994, 165:161-163.
12. Habas C. Functional imaging of the deep cerebellar nuclei: a review. Cerebellum 2010, 9:22-28.
13. Ikai Y., Takada M., Shinonaga Y., Mizuno N. Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience 1992, 51:719-728.
14. Ishibashi T., Wakabayashi J., Ohno Y. 7-Hydroxy-N, N'-di-n-propyl-2-amino tetraline, a preferential dopamine D3 agonist, induces c-fos mRNA expression in the rat cerebellum. Jpn J Pharmacol 2002, 89:309-315.
15. 3 receptors differentially affects spontaneous behaviour and cocaine-induced locomotor activity, reward and CREB phosphorylation. Eur J Neurosci 2005, 22:1741-1750.
16. 3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl) 1995, 122:351-357.
17. Kim Y.S., Shin J.H., Hall F.S., Linden D.J. Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci 2009, 29:8530-8538.
18. 2 receptor sites. Synapse 2011, 65:467-478.
19. Kizer J.S., Palkovits M., Brownstein M.J. The projections of the A8, A9 and A10 dopaminergic cell bodies: evidence for a nigral-hypothalamic-median eminence dopaminergic pathway. Brain Res 1976, 108:363-370.
20. 3 receptors in locomotor activity of rats. J Neural Transm 2008, 115:677-681.
21. 3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav 1995, 52:503-508.
22. 3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration. Neurosci Lett 2010, 485:256-260.
23. Melchitzky D.S., Lewis D.A. Tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in the primate cerebellum. Evidence for a lobular- and laminar-specific dopamine innervation. Neuropsychopharmacology 2000, 22:466-472.
24. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
25. Mortimer A.M. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol 2004, 7(Suppl. 1):S21-S25.
26. 3 receptor in the morphine-induced rewarding effect and hyperlocomotion. J Neurosci 2003, 23:1006-1012.
27. Natesan S., Reckless G.E., Barlow K.B., Nobrega J.N., Kapur S. Amisulpride the 'atypical' atypical antipsychotic - comparison to haloperidol, risperidone and clozapine. Schizophr Res 2008, 105:224-235.
28. Naudon L., Delfs J.M., Clavel N., Lorden J.F., Chesselet M.F. Differential expression of glutamate decarboxylase messenger RNA in cerebellar Purkinje cells and deep cerebellar nuclei of the genetically dystonic rat. Neuroscience 1998, 82:1087-1094.
29. Niznik H.B., Van Tol H.H.M. Dopamine receptor genes: new tools for molecular psychiatry. J Psychiatr Neurosci 1992, 17:158-180.
30. Ohno Y., Shimizu S., Imaki J., Ishihara S., Sofue N., Sasa M., et al. Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens. Neuropharmacology 2008, 55:717-723.
31. 2A antagonist. Pharmacol Biochem Behav 2010, 96:175-180.
32. 6 receptors. Neuropharmacology 2011, 60:201-208.
33. 1 receptor-mediated neurotransmission in the nucleus accumbens of SHR, a rat model of attention deficit/hyperactivity disorder. Neuropharmacology 2012, 63:547-554.
34. Panagopoulos N.T., Papadopoulos G.C., Matsokis N.A. Dopaminergic innervation and binding in the rat cerebellum. Neurosci Lett 1991, 130:208-212.
35. Paxinos G., Watson C. The rat brain in stereotaxic coordites 2007, Elsevier, Manhattan. 6th ed.
36. 3 dopamine receptor in a novel environment. Neuropsychopharmacology 2003, 28:100-107.
37. 3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol Biochem Behav 2007, 86:718-726.
38. 1A receptors. Aging Dis 2013, 4(1):1-13.
39. 1A receptors in alleviating antipsychotic-induced extrapyramidal disorders. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:877-881.
40. 1A agonist alleviates serotonergic potentiation of extrapyramidal disorders via postsynaptic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:86-91.
41. Sokoloff P., Giros B., Martes M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
42. Takada M., Sugimoto T., Hattori T. Tyrosine hydroxylase immunoreactivity in cerebellar Purkinje cells of the rat. Neurosci Lett 1993, 150:61-64.
43. Tatara A., Shimizu S., Shin N., Sato M., Sugiuchi T., Imaki J., et al. Modulation of antipsychotic-induced extrapyramidal side effects by medications for mood disorders. Prog Neuropsychopharmacol Biol Psychiatry 2012, 38:252-259.
44. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10years at the psychopharmacology-molecular biology interface. Psychopharmacology (Berl) 2005, 181:611-638.
45. Yamamoto T., Hassler R., Huber C., Wagner A., Sasaki K. Electrophysiologic studies on the pallido- and cerebellothalamic projections in squirrel monkeys (Saimiri sciureus). Exp Brain Res 1983, 51:77-87.